Investing in the company that is changing the arc of care of critically ill patients
Beginning with stroke, and with numerous indications beyond, our ICU-focused, non-invasive, single-use neurostimulation platform will fundamentally improve the lives of patients by minimizing complications, improving outcomes, and reducing the financial healthcare burden of these fragile patients.
Aurenar is proud to be partnered with METIS. Working with METIS has bolstered support from an ever-growing alliance of world-recognized scientific, industry, and investment leaders, and accelerated the realization of their product and ability to transform patient care.
METIS has world-renowned cerebrovascular expertise that provides Aurenar with superior strategic insight into their beachhead market.
Aurenar is creating a unique, disposable wearable neuromodulation device to change the arc of care for ICU patients by reducing patient morbidities and healthcare costs.
Aurenar has conducted numerous pilot clinical studies that have demonstrated significantly improved patient outcomes, shorter hospital stays, and lower cost of care. These clear and quantifiable benefits are crucial to developing a successful solution, and they are excited to bring their solution to realization.
Aurenar is moving fast. Backed by a comprehensive IP portfolio, exciting results from numerous clinical studies, and a novel non-invasive neuromodulation platform uniquely designed for simple, safe, and effective use in intensive care units, Aurenar is excited to be transforming their vision for better patient care into reality. They are only scratching the surface with hemorrhagic and ischemic stroke, with indications beyond for positive impact in all intensive care units.
